HCR 555 Module 1 Assignment 1: Drug Development From Bench to Market Example

From Bench to Pharmacy Shelf: How a New Drug Is Tested, Judged and Approved in the United States

Student Name

MS in Regulatory Science, Arizona State University

HCR 555: Pharmaceutical Safety and Risk Management

Instructor Name

Month Day, Year

From Bench to Pharmacy Shelf: How a New Drug Is Tested, Judged and Approved in the United States

Introduction

Most compounds that enter development never reach patients. Of drug programs tested in humans between 2000 and 2015, only about one in seven moved from Phase 1 to approval, and in oncology the rate was lower still (Wong et al., 2019). The path is long because each step is designed to answer a different question about safety or benefit before a larger number of people are exposed. This essay traces that path for a hypothetical oral drug for type 2 diabetes, explains how safety and efficacy are detected at each stage and appraises the process through an ethical, legal and social lens.

Discovery and Nonclinical Testing

Development begins with a target, such as an enzyme or receptor that drives disease, and a search for molecules that act on it. Promising candidates are optimized for potency, selectivity and properties such as absorption and half-life. Before any person receives the drug, nonclinical studies in cells and animals characterize pharmacology, toxicity at increasing doses, effects on organs such as the liver and heart, genetic toxicity and, for drugs taken long term, reproductive effects. Studies that support safety must follow Good Laboratory Practice so that their data can be trusted (21 C.F.R. §§ 58.1-58.219). The results determine a safe starting dose for humans and the organs to watch most closely.

The Investigational New Drug Application

To ship an unapproved drug across state lines for testing, the sponsor files an Investigational New Drug application (IND) with the FDA, containing the nonclinical data, manufacturing information and the proposed first protocol (21 C.F.R. §§ 312.1-312.320). The FDA has 30 days to review it and may place the study on clinical hold if subjects would face unreasonable risk. An institutional review board at each site must also approve the protocol and the informed consent process.

Clinical Phases

Phase 1 studies give the drug to small numbers of volunteers, often healthy adults, to establish safety, tolerability, pharmacokinetics and the dose range. Adverse effects are detected through close observation, frequent laboratory tests and electrocardiograms. Phase 2 studies enroll a few hundred patients with the target disease to find the dose that works best and to gather early evidence of efficacy, such as a reduction in hemoglobin A1c, against placebo. Phase 3 trials enroll hundreds to thousands of patients, usually randomized and blinded, to confirm benefit on clinically meaningful endpoints and to characterize side effects that occur too rarely to see in smaller studies. Throughout, investigators record every adverse event, sponsors report serious and unexpected suspected reactions to the FDA under the IND safety reporting rules and independent data monitoring committees review accumulating unblinded data to stop a trial early if harm or overwhelming benefit appears.

The New Drug Application and FDA Review

With Phase 3 complete, the sponsor submits a New Drug Application (NDA) containing every study, the proposed label and manufacturing details (21 C.F.R. §§ 314.1-314.650). FDA reviewers in medicine, statistics, pharmacology, chemistry and clinical pharmacology assess whether the evidence shows the drug is effective for its proposed use and whether its benefits outweigh its risks. The agency may convene an advisory committee, inspect clinical sites and manufacturing plants and negotiate labeling. Expedited pathways, such as priority review, breakthrough therapy designation and accelerated approval based on a surrogate endpoint, shorten the timeline for drugs that address serious conditions with unmet need.

After Approval

Approval begins a new phase of learning. Clinical trials rarely include enough patients, or patients sick enough, to detect uncommon reactions. The FDA may require postmarketing studies or a Risk Evaluation and Mitigation Strategy, and sponsors must report adverse events they learn of after approval. Signals from these reports can lead to label changes, boxed warnings or withdrawal.

ELSI Appraisal

Ethical

The central ethical tension is between access and certainty. Faster pathways bring treatments to patients sooner, but approvals based on surrogate endpoints can leave patients taking drugs whose real benefit is unproven. Phase 1 trials in healthy volunteers also raise questions about payment and risk, since participants receive no medical benefit.

Legal

The legal framework rests on the requirement that drugs be shown to be safe and effective before marketing. Its strength is enforceable standards; its weakness is that postmarketing commitments are sometimes completed late, which weakens the legal promise that surrogate-based approvals will be confirmed.

Social

Trial populations often underrepresent older adults, women and racial and ethnic minorities, yet those groups use the drugs once approved. A diabetes drug tested mostly in middle-aged white men may perform differently in the patients who need it most.

Proposed Solutions

Three changes would address these issues: enforce deadlines for confirmatory trials after accelerated approval, require enrollment plans that match the population with the disease and expand public reporting of trial results so that clinicians can see the evidence behind a label.

Conclusion

The path from bench to market is designed to expose a drug's risks gradually, to larger groups at each step, while proving its benefit. It works imperfectly, because trials are too small and too selective to reveal everything, which is why the system now treats approval as the start of safety surveillance rather than the end of it.

References

Applications for FDA approval to market a new drug, 21 C.F.R. §§ 314.1-314.650 (2025).

Good laboratory practice for nonclinical laboratory studies, 21 C.F.R. §§ 58.1-58.219 (2025).

Investigational new drug application, 21 C.F.R. §§ 312.1-312.320 (2025).

Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20(2), 273-286. https://doi.org/10.1093/biostatistics/kxx069